I think at this point it would be advantageous for any BP to do a CVR (certified value Rights deal) with RVX  with an upfront payment to do BOM2 trial  and milestone payments along the way if the trial meets expecatations,(interm analysis being one  with a final buyout deal at the end if all trials are succesful. Its a win win for Both Pharma and RVX, with minimal risk to any BP as they pay  only if the trials work. upfront $50 million is nothing for a large BP. One can only hope this scenario happens, If not were looking at major dilution to pay for the trials.